BRAIN actively supports the UN Global Compact
BRAIN Biotech AG, Germany, now actively supports the UN Global Compact initiative. With its current products and solutions, the company already addresses at least five UN sustainability goals.
BRAIN Biotech AG (“BRAIN”, ISIN DE0005203947 / WKN 520394) now actively supports the UN Global Compact, a voluntary initiative based on company commitments to implement universal sustainability principles and to advance United Nations goals such as the Sustainable Development Goals (SDGs). By joining the UN Global Compact, BRAIN now formally commits to the values of the world's largest initiative for corporate social responsibility and thus commits to ten universal principles concerning human rights, labour standards, environment and climate as well as the prevention of corruption.
With the current products and solutions, BRAIN already directly addresses at least five of the UN Sustainable Development Goals (SDG):
- SDG 2, Zero Hunger: natural compounds for food preservation
- SDG 3, Good Health & Well-Being: natural sugar replacement, salt replacement and salt taste enhancers, natural aromas, bioactive plant cosmetic and chronical wound treatment
- SDG 6, Clean Water & Sanitation: green mining solutions to replace chemical hazards
- SDG 9, Industry, Innovation & Infrastructure: biotechnological production, improving production efficiencies for resource conservation, fermented food from side-streams, microbial CO2 usage
- SDG 12, Responsible Consumption & Production: green and urban mining (bio-based recycling)
Adriaan Moelker, CEO BRAIN Biotech AG, states: “We take pride to support the UN Global Compact, one of the globally most important initiatives for the corporate sector to adopt sustainable and socially responsible policies. BRAIN develops products and services, which change the way industrial production is done. Our natural and sustainable bio-based processes accelerate the economic transformation to a circular economy. In addition, we incorporate sustainability aspects and good corporate governance in the daily management of our operations. Acting responsibly is elementary for all of BRAIN’s stakeholders so that I am personally heading our ESG initiatives. We are currently preparing a corporate sustainability report to document our goals and their implementation also under the framework of the UN Global Compact.”
About UN Global Compact
The United Nations Global Compact is a non-binding United Nations pact to encourage businesses and firms worldwide to adopt sustainable and socially responsible policies, and to report on their implementation. The UN Global Compact is a principle-based framework for businesses, stating ten principles in the areas of human rights, labor, the environment and anti-corruption. Under the Global Compact, companies are brought together with UN agencies, labor groups and civil society. Cities can join the Global Compact through the Cities Programme.
Further details at: https://www.unglobalcompact.org/what-is-gc
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.